Menu

Charles River Laboratories International, Inc. CRL

Full chart Compare
Set alert

Price alert · CRL

All alert types
353.34 USD +15.82 (+4.69%)

At closeNov 9, 2026, 4:00 PM EST

354.92 +1.58 +0.45%

After hours · Nov 9, 4:00 PM ET

342.00 Day range 358.77
146.20 52-week range 379.63
YTD
+77.13%
1 year
+110.26%
Market cap
16.93B
Revenue (ttm)
3.98B
Profit margin
1.01%
EPS (ttm)
0.92
Shares out
47.92M
P/E ratio
384.06
Forward P/E
27.37
YTD return
+77.13%
1-year return
+110.26%
Volume
943.08K
Avg volume
1.07M
Open
343.44
Previous close
337.52
Day's range
342.00 – 358.77
52-week range
146.20 – 379.63
Beta
1.34
Analysts
Buy
Price target
349.00 (-1.2%)
Earnings date
Feb 17, 2027

5D +13.49 (+3.97%)

320340360TueWedThuFriMon353.34

Key statistics

Enterprise value
18.87B
PEG ratio
0.12
Price / sales
4.27
Price / book
5.26
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-2.20%
Free cash flow
443.24M
Total cash
200.38M
Total debt
2.85B
Return on equity
1.27%
Short % of float
6.84%
50-day average
305.60
200-day average
224.56

Financials — quick view

All financials
CRL Revenue — quarterly 982.73M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CRL Net income — quarterly 333.07M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CRL EPS — quarterly 6.97
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

CRL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 26, 20263.29———
Nov 4, 2026Sep 26, 20262.973.09+0.12+4.04%
Aug 5, 2026Jun 27, 20262.743.02+0.28+10.22%
May 7, 2026Mar 28, 20261.962.06+0.10+5.10%
Feb 18, 2026Dec 27, 20252.332.39+0.06+2.58%
Nov 5, 2025Sep 27, 20252.322.43+0.11+4.74%

Upgrades / downgrades

CRL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026UBSmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026BarclaysmainOverweightOverweight
Nov 5, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026Morgan StanleymainOverweightOverweight
Sep 28, 2026JefferiesmainBuyBuy

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
criver.com

News

Your note

Sign in to keep a note on CRL — it syncs with the Stock Master app.

Insider holders

CRL insider holders
InsiderRelationLatest transactionDateShares held
COLEMAN GLENN GChief Financial OfficerStock Award(Grant)May 28, 202627,752
CREAMER VICTORIA LOfficerConversion of Exercise of derivative securityAug 5, 202630,051
FOSTER JAMES CDirectorConversion of Exercise of derivative securityOct 21, 2026233,410
GIRSHICK BIRGITChief Executive OfficerStock GiftAug 18, 202679,288
KNELL MICHAEL GUNNAROfficerConversion of Exercise of derivative securityAug 5, 202611,852
LAPLUME JOSEPH WOfficerStock GiftAug 9, 202631,041

Institution ownership

CRL institution ownership
Holder% heldSharesValueReported
FMR, LLC8.85%4,239,7521.50BJun 29, 2026
Blackrock Inc.7.93%3,798,5601.35BJun 29, 2026
Vanguard Capital Management LLC6.57%3,149,2881.12BJun 29, 2026
Invesco Ltd.6.23%2,984,7851.06BJun 29, 2026
Harris Associates L.P.4.68%2,241,144794.32MJun 29, 2026
Vanguard Portfolio Management LLC4.61%2,210,979783.63MJun 29, 2026

Fund ownership

CRL fund ownership
Holder% heldSharesValueReported
Fidelity Contrafund4.31%2,065,737732.15MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%1,530,171542.33MJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.13%1,498,000530.93MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%1,247,732442.23MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%1,104,850391.59MJun 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund1.64%784,906278.19MAug 30, 2026